The global benign prostatic hyperplasia treatment market was valued at USD 12.5 Billion in 2024 and is projected to reach USD 18.5 Billion by 2033, growing at a CAGR of 4.4% during the forecast period of 2025-2033. Factors driving the market are the increase in BPH prevalence among the growing geriatric male population, development of minimally intrusive therapies, improvements in drug formulations, and increased awareness among urological patients. The above 34.8% share of North America in 2024 can be attributed to the advanced healthcare infrastructure, high expenditure on healthcare, established distribution channel, and reimbursement policies. The study provides a detailed analysis of the industry, including the Benign Prostatic Hyperplasia Treatment market report, trends, growth, size, and industry growth forecast.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Benign Prostatic Hyperplasia Treatment Market Key Takeaways

• Current Market Size: USD 12.5 Billion in 2024
• CAGR: 4.4%
• Forecast Period: 2025-2033
• North America dominates with over 34.8% market share in 2024, driven by advanced healthcare systems.
• Alpha-blockers lead drug class segment with highest market share for symptomatic relief.
• Drug class represents largest treatment type segment due to first-line treatment preference.
• Minimally invasive surgeries gaining traction with improved patient outcomes and reduced recovery times.
• Aging male population worldwide driving sustained market growth and treatment demand.

Request for a Free Sample Report: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market/requestsample

Market Growth Factors

The increasing global population of aging men is the major driver for the BPH (benign prostatic hyperplasia) treatment market, as the geriatric male population is increasing at a rapid rate across the world. Because life expectancy is increasing worldwide, the number of men affected by the most common age-related condition, BPH, has also increased. The increase has mainly been in men 50 years or older. Histopathological BPH is common in approximately half of men at age 60 and 90% of men at age 85. The population ages with rapidity and the over-65 population will double from 700 million during 2010 to 1.4 billion by 2030. This considerable expansion in the target population for BPH therapies will occur. The number of minimally intrusive procedures is projected for dramatic increase, as these procedures offer benefits such as shorter recovery periods and less risk of complications, driving important market growth.

Laser therapies, prostatic urethral lifts, and transurethral therapies are other procedures that tend to have shorter hospital stays, faster recovery, and a lower chance of complications than more intrusive surgical procedures. Using robotic-assisted and novel surgical procedures and having access to them continues to improve the precision and improve the outcomes of these procedures with improved overall patient experience, particularly in patients who do not want to take a lifelong medication.

Drug formulations increase as do combination therapies. Pharmaceutical companies are developing new formulations of existing drugs and exploring the combination therapy, targeting multiple pathways involved in BPH progression. Alpha-blockers, 5-alpha-reductase inhibitors, and phosphodiesterase-5 enzyme inhibitors are the main drug classes for LUTS. Newer versions of these drugs are in development to improve effectiveness. New drug delivery systems and continuous or prolonged release formulations have led to improved compliance and treatment outcome. Combination therapies for symptom control as well as disease modification have broadened the treatment options available. Continued drug developments coupled with favorable regulations and patent extensions increase the treatment options for patients and healthcare providers.

Market Segmentation

Analysis by Treatment Type:

• Drug Class: Includes alpha-blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 enzyme inhibitors, and others. Alpha-blockers account for highest market share, offering rapid symptomatic relief by relaxing muscles within prostate and bladder neck to facilitate urine flow. They serve as first-line drugs due to efficacy, availability, and fewer side effects.
• Minimally Invasive Surgeries: Include transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), robotic surgeries, prostatic urethral lifts, and others. These procedures offer alternatives to traditional surgery with reduced recovery times and complications.
• Laser Therapy: Encompasses various laser-based procedures including holmium laser enucleation (HoLEP) and photoselective vaporization, offering precise tissue removal with minimal bleeding and faster recovery.
• Others: Include alternative and complementary therapies, investigational treatments, and emerging therapeutic approaches for BPH management.

Analysis by Drug Class:

• Alpha-Blockers: Lead the segment with highest market share, providing quick symptomatic relief by relaxing prostate and bladder neck muscles. Widely prescribed as first-line treatment due to proven efficacy and tolerability profile.
• 5-Alpha-Reductase Inhibitors (5-ARIs): Target disease progression by reducing prostate size over time. Often used in combination therapy for patients with larger prostates.
• Phosphodiesterase-5 Enzyme Inhibitors: Offer dual benefits for patients with both BPH and erectile dysfunction, improving urinary symptoms and sexual function.
• Others: Include combination drugs and emerging therapeutic classes targeting novel mechanisms of action.

Analysis by End-Use:

• Hospitals: Provide comprehensive BPH treatment including surgical procedures, advanced diagnostics, and multidisciplinary care for complex cases.
• Clinics: Offer outpatient management, medication prescriptions, and follow-up care for BPH patients in community settings.
• Ambulatory Surgical Centers: Specialize in minimally invasive procedures with same-day discharge capabilities for appropriate candidates.
• Others: Include specialized urology centers, research institutions, and telemedicine platforms providing BPH consultations and management.

Analysis by Region:

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa

Regional Insights

North America accounted for the highest share of the industry over 34.8% in 2024. This is due to the well-established healthcare infrastructure in the region and high healthcare spending, established distribution channels, and presence of top pharmaceutical and medical device manufacturers within the region. The prevalence of BPH is high among older males. Quick uptake of medications and surgical procedures is also helped by favorable reimbursement, and high insurance penetration. Available medications and therapies are kept up-to-date by an ever-growing series of trials and research programs. In the United States, there is a wide availability of medical resources, specialized urology units and patient education programs.

Recent Developments & News

In May 2024, Sumitomo Pharma America announced that the FDA accepted its supplemental New Drug Application regarding vibegron to treat the symptoms of overactive bladder in men who take pharmacological therapy for benign prostatic hyperplasia with GEMTESA. Vibegron, upon approval, would be the first beta-3 agonist men can use. Pharmaceutical companies do continuing research and clinical trials for developing more effective treatments for BPH including drug formulations with improved efficacy and safety, minimally intrusive procedures, and combination therapy to optimize treatment outcomes and improve quality of life. Medical device manufacturers are developing surgical technologies and instruments to increase the safety and precision of BPH procedures.

Key Players

• Abbott Laboratories
• Allergan Plc (AbbVie Inc.)
• Asahi Kasei Corporation
• Astellas Pharma Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• GlaxoSmithKline Plc
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201-971-6302